QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.117150v1 322/1/30    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peterson, E. C. Articles by Owens, S. M. Search for Related Content PubMed PubMed Citation Articles by Peterson, E. C. Articles by Owens, S. M. Pubmed/NCBI databases Protein UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB d-METHAMPHETAMINE Medline Plus Health Information Methamphetamine

NEUROPHARMACOLOGY

Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse

Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (E.C.P., M.G., Y.C., S.M.O.); Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas (R.L.G., R.H., H.L.); and Research Triangle Institute, Research Triangle Park, North Carolina (F.I.C.)

When generating monoclonal antibodies (mAb) against small molecules, the chemical composition and molecular orientation of the drug-like hapten on the antigen is a crucial determinant. This is especially important when attempting to discover therapeutic mAb against the drugs of abuse (+)-methamphetamine [(+)-METH], (+)-amphetamine [(+)-AMP], and the related compound (+)-3,4-methylenedioxymethamphetamine [(+)-MDMA, the plus isomer in the racemic mixture known as MDMA or ecstasy]. The goal of these studies was to design and synthesize (+)-METH-like haptens with structural attributes that could make them effective for generating monoclonal antibodies for treating medical problems associated with these stimulant drugs of abuse. Five prototype (+)-METH-like haptens, which mimic structural aspects of these drugs, were synthesized and used to generate mAb. After screening for anti-(+)-METH IgG antibodies in more than 25,000 potential mouse hybridoma cell lines, one prototype mAb from each of the five haptens was selected and studied in detail for molecular properties and preclinical efficacy. The amino acid sequences of the IgG-variable regions, structural models, affinity, and ligand specificity of each mAb were then used to help elucidate important therapeutic characteristics. Four of these antibodies exhibited high affinity and specificity to (+)-METH and (+)-MDMA; whereas one antibody (designated mAb4G9) exhibited high affinity and specificity to (+)-METH, (+)-MDMA, and (+)-AMP, without significant cross-reactivity against other METH-like ligands, over-the-counter medications, or endogenous neurotransmitters. Considered together, discovery of mAb4G9 and the other antibodies in this report represent an important step in understanding the process for custom design of drug class-specific therapeutic antibodies for the treatment of drug addiction.

Address correspondence to: Dr. S. Michael Owens, Department of Pharmacology and Toxicology, College of Medicine, #611, University of Arkansas for Medical Sciences, 4301 W. Markham, Little Rock, AR 72205. E-mail: mowens{at}uams.edu

This article has been cited by other articles:

				E. C. Peterson, E. M. Laurenzana, W. T. Atchley, H. P. Hendrickson, and S. M. Owens Development and Preclinical Testing of a High-Affinity Single-Chain Antibody against (+)-Methamphetamine J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 124 - 133. [Abstract] [Full Text] [PDF]